Aumolertinib Combined Intrathecal Chemotherapy for Leptomeningeal Metastasis From EGFR-Mutated NSCLC and Prognostic Value of Dynamic Changes in cfDNA Profiles
Clinical trial NCT05810350 · UNKNOWN
Trial details
- NCT number
- NCT05810350
- Sponsor
- Three Gorges Hospital of Chongqing University
- Status
- UNKNOWN
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2023-01-01
- Primary completion
- 2024-12-31
- Enrollment
- 40
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.